These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 15923592)

  • 1. Gefitinib has the potential of activating cell immunity against malignant cells.
    Kanazawa S; Muramatsu M; Kinoshita Y; Yamaguchi K; Nomura S
    J Clin Oncol; 2005 Jun; 23(16):3865-6; author reply 3866-7. PubMed ID: 15923592
    [No Abstract]   [Full Text] [Related]  

  • 2. Molecular markers to predict response to gefitinib: EGFR, ErbB-2, or more?
    Normanno N; Di Maio M; Perrone F; Campiglio M
    J Clin Oncol; 2004 May; 22(10):2035-6; author reply 2036-7. PubMed ID: 15143103
    [No Abstract]   [Full Text] [Related]  

  • 3. Biomarkers of response to gefitinib in non-small-cell lung cancer.
    Carbone DP
    Nat Clin Pract Oncol; 2004 Dec; 1(2):66-7. PubMed ID: 16264818
    [No Abstract]   [Full Text] [Related]  

  • 4. The current situation: erlotinib (Tarceva) and gefitinib (Iressa) in non-small cell lung cancer.
    Comis RL
    Oncologist; 2005 Aug; 10(7):467-70. PubMed ID: 16079313
    [No Abstract]   [Full Text] [Related]  

  • 5. Maintenance therapy comes of age for non-small-cell lung cancer, but at what cost?
    Shepherd FA
    J Clin Oncol; 2011 Nov; 29(31):4068-70. PubMed ID: 21969515
    [No Abstract]   [Full Text] [Related]  

  • 6. Gefitinib versus cetuximab in lung cancer: round one.
    Minna JD; Peyton MJ; Gazdar AF
    J Natl Cancer Inst; 2005 Aug; 97(16):1168-9. PubMed ID: 16106015
    [No Abstract]   [Full Text] [Related]  

  • 7. Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer.
    Han SW; Hwang PG; Chung DH; Kim DW; Im SA; Kim YT; Kim TY; Heo DS; Bang YJ; Kim NK
    Int J Cancer; 2005 Jan; 113(1):109-15. PubMed ID: 15386420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Re: Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer.
    de Braud F; De Pas T; Spaggiari L; Veronesi G; Curigliano G; Noberasco C; Pelosi G
    J Natl Cancer Inst; 2005 Mar; 97(6):461-2; author reply 462-3. PubMed ID: 15770011
    [No Abstract]   [Full Text] [Related]  

  • 9. Gefitinib. Still no convincing results in non-small cell lung cancer.
    Prescrire Int; 2010 Jun; 19(107):113. PubMed ID: 20738034
    [No Abstract]   [Full Text] [Related]  

  • 10. Predictors of clinical response of non-small cell cancer to gefitinib.
    Ardizzoni A; Tiseo M
    JAMA; 2004 Apr; 291(13):1563; author reply 1563-4. PubMed ID: 15069041
    [No Abstract]   [Full Text] [Related]  

  • 11. Autophagy facilitates the EGFR-TKI acquired resistance of non-small-cell lung cancer cells.
    Liu D; Yang Y; Zhao S
    J Formos Med Assoc; 2014 Mar; 113(3):141-2. PubMed ID: 24630031
    [No Abstract]   [Full Text] [Related]  

  • 12. Gefitinib plus docetaxel in non-small-cell lung cancer.
    Costa DB; Kobayashi S
    Lancet; 2009 Feb; 373(9663):541; author reply 542. PubMed ID: 19217979
    [No Abstract]   [Full Text] [Related]  

  • 13. Gefitinib first or gefitinib second: is timing everything in the treatment of EGFR mutant non-small cell lung cancer?
    Jänne PA
    Am J Respir Crit Care Med; 2008 Oct; 178(8):783-5. PubMed ID: 18832554
    [No Abstract]   [Full Text] [Related]  

  • 14. Gefitinib plus docetaxel in non-small-cell lung cancer.
    Zalcman G; Bergot E
    Lancet; 2009 Feb; 373(9663):541; author reply 542. PubMed ID: 19217981
    [No Abstract]   [Full Text] [Related]  

  • 15. Predicting sensitivity of non-small-cell lung cancer to gefitinib: is there a role for P-Akt?
    Pao W; Miller VA; Venkatraman E; Kris MG
    J Natl Cancer Inst; 2004 Aug; 96(15):1117-9. PubMed ID: 15292378
    [No Abstract]   [Full Text] [Related]  

  • 16. Epidermal growth factor receptor inhibitors, gefitinib and erlotinib (Tarceva , OSI-774), in the treatment of bronchioloalveolar carcinoma.
    DeGrendele H
    Clin Lung Cancer; 2003 Sep; 5(2):83-5. PubMed ID: 14596689
    [No Abstract]   [Full Text] [Related]  

  • 17. Targeting the epidermal growth factor receptor a new strategy in cancer treatment.
    Gianni L; Grasselli G
    Suppl Tumori; 2002; 1(4):S60-1. PubMed ID: 12415824
    [No Abstract]   [Full Text] [Related]  

  • 18. Failing survival advantage in crucial trial, future of Iressa is in jeopardy.
    Twombly R
    J Natl Cancer Inst; 2005 Feb; 97(4):249-50. PubMed ID: 15713955
    [No Abstract]   [Full Text] [Related]  

  • 19. Increasing osteoblastic lesions as a manifestation of a major response to gefitinib.
    Garfield D
    J Thorac Oncol; 2006 Oct; 1(8):859-60. PubMed ID: 17409972
    [No Abstract]   [Full Text] [Related]  

  • 20. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.
    Brugger W; Triller N; Blasinska-Morawiec M; Curescu S; Sakalauskas R; Manikhas GM; Mazieres J; Whittom R; Ward C; Mayne K; Trunzer K; Cappuzzo F
    J Clin Oncol; 2011 Nov; 29(31):4113-20. PubMed ID: 21969500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.